Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Single Ascending Dose (SAD) Trial of SNDX-6352 Assessing the Safety, Pharmacokinetics and Pharmacodynamics of the Anti-CSF-1R Monoclonal Antibody (SNDX-6352) in Healthy Volunteers

Next Previous
X
Search
Trial Profile

A Phase I Single Ascending Dose (SAD) Trial of SNDX-6352 Assessing the Safety, Pharmacokinetics and Pharmacodynamics of the Anti-CSF-1R Monoclonal Antibody (SNDX-6352) in Healthy Volunteers

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Nov 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axatilimab (Primary)
  • Indications Cancer; Solid tumours
  • Focus Adverse reactions; First in man

    • Most Recent Events

    • 11 Nov 2017 According to a Syndax Pharmaceuticals media release, data from this trial were presented at the Society of Immunotherapy of Cancer (SITC) Annual Scientific Meeting
    • 11 Nov 2017 Results published in the Syndax Pharmaceuticals Media Release
    • 07 Nov 2017 According to a Syndax Pharmaceuticals media release, data from this trial will be presented at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top